ACM
AXDX

Aquatic Capital Management’s Accelerate Diagnostics AXDX Stock Holding History

Aquatic Capital Management’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-160
Closed -$2K – 1195
2022
Q1 		$2K Sell
160
-170
-52% -$4.84K ﹤0.01% 954
2021
Q4 		$17K Buy
+330
New +$18.4K 0.03% 639

Other funds holding AXDX

GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
CIA
Cladis Investment Advisory Billings, Montana $214M AUM 45.87% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BAM
Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return

Aquatic Capital Management's AXDX Position: Q2 2022 in Review

Aquatic Capital Management sold out of Accelerate Diagnostics (AXDX) in Q2 2022, closing a stake of 160 shares — an estimated $2K sold.

Aquatic Capital Management first reported a position in AXDX in Q4 2021 and held it in 2 quarters. The position peaked at $17K in Q4 2021. 74 funds tracked by Wall St. Rank hold AXDX as of Q2 2022.

  • Aquatic Capital Management reported no remaining Accelerate Diagnostics position as of Q2 2022 after selling out during the quarter.
  • Aquatic Capital Management sold 160 Accelerate Diagnostics shares in Q2 2022, an estimated $2K.
  • Aquatic Capital Management first reported a position in Accelerate Diagnostics in Q4 2021 and held it in 2 quarters.
  • Aquatic Capital Management's Accelerate Diagnostics position peaked at $17K in Q4 2021.
  • 74 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2022.

Based on Aquatic Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.